[go: up one dir, main page]

DK1636206T3 - Imidazolderivater som glutamatreceptorantagonister - Google Patents

Imidazolderivater som glutamatreceptorantagonister

Info

Publication number
DK1636206T3
DK1636206T3 DK04739484T DK04739484T DK1636206T3 DK 1636206 T3 DK1636206 T3 DK 1636206T3 DK 04739484 T DK04739484 T DK 04739484T DK 04739484 T DK04739484 T DK 04739484T DK 1636206 T3 DK1636206 T3 DK 1636206T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
glutamate receptor
imidazole derivatives
imidazole
derivatives
Prior art date
Application number
DK04739484T
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Eric Vieira
Richard Hugh Phillip Porter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1636206T3 publication Critical patent/DK1636206T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK04739484T 2003-06-05 2004-06-01 Imidazolderivater som glutamatreceptorantagonister DK1636206T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03012200 2003-06-05
PCT/EP2004/005881 WO2004108701A1 (en) 2003-06-05 2004-06-01 Imidazole derivatives as glutmate receptor antagonists

Publications (1)

Publication Number Publication Date
DK1636206T3 true DK1636206T3 (da) 2008-02-11

Family

ID=33483899

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04739484T DK1636206T3 (da) 2003-06-05 2004-06-01 Imidazolderivater som glutamatreceptorantagonister

Country Status (38)

Country Link
US (3) US7332510B2 (da)
EP (1) EP1636206B1 (da)
JP (1) JP4401384B2 (da)
KR (1) KR100778948B1 (da)
CN (1) CN100408572C (da)
AR (1) AR044478A1 (da)
AT (1) ATE377008T1 (da)
AU (1) AU2004245208B2 (da)
BR (1) BRPI0411095B8 (da)
CA (1) CA2527315C (da)
CL (1) CL2004001347A1 (da)
CR (1) CR8094A (da)
CY (1) CY1107856T1 (da)
DE (1) DE602004009796T2 (da)
DK (1) DK1636206T3 (da)
EA (1) EA010577B1 (da)
EC (1) ECSP056202A (da)
ES (1) ES2294504T3 (da)
GT (1) GT200400117A (da)
HN (1) HN2004000208A (da)
HR (1) HRP20070529T3 (da)
IL (1) IL171930A (da)
MA (1) MA27881A1 (da)
MX (1) MXPA05013149A (da)
MY (2) MY137272A (da)
NO (1) NO332143B1 (da)
NZ (1) NZ543637A (da)
PA (1) PA8604101A1 (da)
PE (1) PE20050162A1 (da)
PL (1) PL1636206T3 (da)
PT (1) PT1636206E (da)
RS (1) RS53183B (da)
SI (1) SI1636206T1 (da)
TN (2) TNSN05309A1 (da)
TW (1) TWI338007B (da)
UA (1) UA80888C2 (da)
WO (1) WO2004108701A1 (da)
ZA (2) ZA200509807B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
US7452909B2 (en) 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
PT2125779T (pt) * 2006-12-21 2016-07-19 Hoffmann La Roche Polimorfos de um antagonista de um recetor de mglur5
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
UA114529C2 (uk) * 2012-10-18 2017-06-26 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як модулятори активності рецептора mglur5
EP2909178B1 (en) * 2012-10-18 2016-10-05 F. Hoffmann-La Roche AG Ethynyl derivatives as modulators of mglur5 receptor activity
CA3018375A1 (en) * 2016-03-30 2017-10-05 Carin Sjolund Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
WO2021110574A1 (en) * 2019-12-02 2021-06-10 F. Hoffmann-La Roche Ag Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors
KR20230027145A (ko) 2020-06-05 2023-02-27 노에마 파르마 아게 결절성 경화증 복합증의 치료 방법
TW202220649A (zh) * 2020-07-30 2022-06-01 瑞士商諾埃瑪製藥公司 三叉神經痛之治療方法
EP4658268A1 (en) 2023-02-02 2025-12-10 Noema Pharma AG Methods of treatment of dravet syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508560A (en) * 1981-11-11 1985-04-02 Ciba Geigy Corporation Certain pyridylacetylene compounds, compositions containing same and herbicidal methods of use
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780009B2 (en) * 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
MXPA03004862A (es) * 2000-12-04 2005-02-14 Hoffmann La Roche Derivados de feniletenilo o feniletinilo como antagonistas del receptor de glutamato.
AU2002360621B2 (en) * 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
WO2004038374A2 (en) * 2002-10-24 2004-05-06 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding
TWI292318B (en) * 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives

Also Published As

Publication number Publication date
DE602004009796T2 (de) 2008-08-28
HN2004000208A (es) 2009-02-03
US20080119489A1 (en) 2008-05-22
CN1802367A (zh) 2006-07-12
ZA200609681B (en) 2008-06-25
DE602004009796D1 (de) 2007-12-13
JP4401384B2 (ja) 2010-01-20
JP2006526588A (ja) 2006-11-24
BRPI0411095B8 (pt) 2021-05-25
AU2004245208A1 (en) 2004-12-16
AR044478A1 (es) 2005-09-14
KR20060057537A (ko) 2006-05-26
US20080103306A1 (en) 2008-05-01
WO2004108701A1 (en) 2004-12-16
TNSN05309A1 (fr) 2007-07-10
TNSN06391A1 (fr) 2008-02-22
PT1636206E (pt) 2008-01-28
EA200501887A1 (ru) 2006-10-27
IL171930A0 (en) 2006-04-10
HRP20070529T3 (hr) 2008-05-31
EP1636206A1 (en) 2006-03-22
CY1107856T1 (el) 2013-06-19
RS20050892A (sr) 2007-12-31
GT200400117A (es) 2005-02-07
CN100408572C (zh) 2008-08-06
CR8094A (es) 2006-05-30
TWI338007B (en) 2011-03-01
NO332143B1 (no) 2012-07-02
MY137272A (en) 2009-01-30
SI1636206T1 (sl) 2008-02-29
IL171930A (en) 2010-12-30
US7973165B2 (en) 2011-07-05
TW200509920A (en) 2005-03-16
US20040248888A1 (en) 2004-12-09
ES2294504T3 (es) 2008-04-01
NO20055465L (no) 2005-11-18
AU2004245208B2 (en) 2007-04-26
US8481548B2 (en) 2013-07-09
BRPI0411095A (pt) 2006-07-18
EP1636206B1 (en) 2007-10-31
US7332510B2 (en) 2008-02-19
KR100778948B1 (ko) 2007-11-28
HK1093070A1 (zh) 2007-02-23
MA27881A1 (fr) 2006-05-02
EA010577B1 (ru) 2008-10-30
PL1636206T3 (pl) 2008-04-30
CA2527315C (en) 2010-08-10
ATE377008T1 (de) 2007-11-15
NZ543637A (en) 2008-04-30
RS53183B (sr) 2014-06-30
BRPI0411095B1 (pt) 2018-04-03
ECSP056202A (es) 2006-04-19
CL2004001347A1 (es) 2005-05-06
CA2527315A1 (en) 2004-12-16
UA80888C2 (en) 2007-11-12
MXPA05013149A (es) 2006-03-17
ZA200509807B (en) 2006-12-27
MY143353A (en) 2011-04-29
PE20050162A1 (es) 2005-03-22
PA8604101A1 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
CY2017032I1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
DK1501809T3 (da) Trizolderivater som tachykininreceptorantagonister
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK2208727T3 (da) Diarylethere som opioidreceptorantagonister
NO20054951D0 (no) Prostaglandinanaloger som EP4-reseptorantagonister
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
DK1539742T3 (da) Indolderivater, der er nyttige som histamin H3-antagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
EP1577301A4 (en) diamine
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
NO20052797D0 (no) Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK1802307T3 (da) Pyrrolidinderivater som histamin-receptor-ligander
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
DK1740569T3 (da) Imidazol-derivater som TAFla-inhibitorer
DK1763517T3 (da) Pyrimidinderivater som 11beta-HSD1-inhibitorer
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
DK1560828T3 (da) Imidazoquinolinderivater som adenosin-A3-receptorligander
DK1928821T3 (da) Carboxamidderivater som muscarinreceptorantagonister
NO20055758D0 (no) Heteroarylsubstituerte imidazolderivater som glutamatreseptorantagonister